Secukinumab Shows Promise as a Treatment Option for Giant Cell Arteritis

Written by RheuMD on 26 May 2023. Posted in Rheumatology News & Perspectives

Giant cell arteritis (GCA) is a challenging condition that requires effective treatment options to reduce the reliance on glucocorticoids. In a recent phase 2 study, researchers evaluated…

Relationship Between Rheumatoid Arthritis Treatments and Cardiovascular Health

Written by RheuMD on 25 May 2023. Posted in Rheumatology News & Perspectives

Rheumatoid arthritis (RA) is a complex condition that not only affects the joints but also poses a risk to cardiovascular health. Inflammation plays a significant role in this increased…

Individualized Rituximab Treatment in ANCA-Associated Vasculitides

Written by RheuMD on 23 May 2023. Posted in Rheumatology News & Perspectives

A recent ancillary study conducted as part of the MAINRITSAN 2 trial has shed light on the interindividual variability in response to rituximab treatment in patients with antineutrophil…

Lenabasum in Diffuse Cutaneous Systemic Sclerosis: Insights from a Phase 3 Study

Written by RheuMD on 25 May 2023. Posted in Rheumatology News & Perspectives

In the quest to find effective treatments for diffuse cutaneous systemic sclerosis (dcSSc), researchers have explored lenabasum, a medication that targets the cannabinoid type 2 receptor. A…

An Irreversible Covalent Bruton's Tyrosine Kinase Inhibitor Shows Promising Results in Rheumatoid Arthritis Patients with Methotrexate Resistance: Phase IIa Trial Findings